Summary#
This bill would require Medicare to cover certain blood-based tests for early detection of Alzheimer’s disease and related dementias. It adds a new definition of “Alzheimer’s disease and related dementias early detection screening tests” and includes those tests among items for which Medicare payment can be made. The coverage would apply to tests furnished on or after January 1, 2028.
Key changes:
- Creates a new category of covered tests for early, pre-symptomatic detection of Alzheimer’s and related dementias.
- Requires the test to have FDA clearance, classification, or approval before Medicare will cover it.
- Names genomic sequencing blood or blood product tests as covered examples.
- Allows the Health and Human Services Secretary to approve other equivalent tests (for example: single-analyte blood tests, cell-free nucleic acid tests, multiplex panels, whole genome/exome/transcriptome, protein expression tests, and medical imaging based on biospecimens) if they give comparable results.
- Adds these tests to the list of items for which Medicare payment may be made.
What it means for you#
- Medicare beneficiaries: If you have Medicare, certain FDA-cleared or approved blood-based tests for early detection of Alzheimer’s or related dementias could be covered beginning January 1, 2028. The bill does not say who qualifies by age, risk, or symptoms.
- People at risk or worried about dementia: More types of blood tests may become available and affordable under Medicare if they are FDA-cleared and judged equivalent by the Secretary.
- Doctors and clinics: Providers may be able to order and bill Medicare for these covered tests once they meet the bill’s criteria.
- Laboratories and test makers: Companies with FDA-cleared or approved blood-based dementia tests would be eligible for Medicare payment for those tests. The Secretary can also designate additional test types as equivalent.
- Medicare program administrators: CMS (the agency that runs Medicare) would need to incorporate these tests into coverage and payment rules and decide how to apply the Secretary’s authority to identify “equivalent” tests.
Expenses#
No publicly available information.
Possible cost or administrative areas the bill raises:
- This could increase Medicare spending because more tests might be paid for by the program.
- CMS would likely need to establish payment rules, claims processing changes, and oversight for these tests.
- There could be costs related to follow-up care after a positive screening (diagnostic work-ups, specialist visits, treatments), but the bill does not address those costs.
- Laboratories and providers would face costs to meet billing, reporting, or validation requirements; those costs are not specified.
Proponents' View#
- The bill appears intended to expand access to early detection of Alzheimer’s and related dementias through covered blood-based tests.
- Supporters may argue that covering validated tests could help detect disease earlier, which could allow earlier planning, monitoring, or treatment.
- Requiring FDA clearance, classification, or approval sets an evidentiary threshold for tests before Medicare will pay for them.
- Allowing the Secretary to recognize “equivalent” tests aims to include new or different testing technologies that produce comparable results.
Opponents' View#
- One concern is cost: the bill does not include a fiscal estimate, so the effect on Medicare spending is unclear.
- The bill does not specify who should be screened (age, risk factors, frequency), leaving questions about appropriate use and possible overuse.
- It is unclear how Medicare will handle follow-up care, confirmatory testing, counseling, or treatment after a positive screen.
- The definition covers many test types and gives the Secretary discretion to add “equivalent” tests; this may raise questions about how strict the standards for equivalence will be.
- The bill does not address accuracy, false positives or negatives, or how to prevent unnecessary procedures resulting from screening.